Table 2 Summary of ASCO value framework for RCC therapeutics
Treatment | Clinical benefit | Toxicity | Bonus point | Net health benefit | |||
|---|---|---|---|---|---|---|---|
Tail of Curve | Palliation | Quality of Life | Treatment-free interval | ||||
Pazopanib | 0 | 1 | 0 | 0 | 10 | 0 | 11.0 |
Nivolumab + Ipilimumab | 37 | 4.9 | 0 | 0 | 0 | 0 | 41.9 |
Axitinib + Avelumab | 24.8 (overall) | −2.4 | 0 | NA | NA | 0 | 22.4 (overall) |
Axitinib+ Pembrolizumab | 47 | 1.7 | 0 | NA | NA | 0 | 48.7 |
Lenvatinib+Pembrolizumab | 34 | 1.2 | 0 | NA | NA | 0 | 35.2 |
Cabozantinib+Nivolumab | 40 | 0.8 | 0 | NA | 10 | 0 | 50.8 |